Literature DB >> 7683247

Low bone mineral density in adults with previous hypothalamic-pituitary tumors: correlations with serum growth hormone responses to GH-releasing hormone, insulin-like growth factor I, and IGF binding protein 3.

R G Bing-You1, M C Denis, C J Rosen.   

Abstract

The adverse consequences of growth hormone (GH) deficiency (GHD) on bone growth in children is well described. Whether adult GHD is associated with bone loss is unknown. We evaluated 14 patients with hypothalamic-pituitary tumors (HPT) acquired during adulthood (5 men, 9 women; mean age = 48.1 +/- 4.6 years; mean BMI = 28.8 +/- 1.7) and 14 age-, sex-, and weight-matched controls. Nine HPT patients were receiving gonadal steroid replacement therapy for a mean of 11 years. All subjects had basal IGF-I and IGFBP-3 levels prior to testing with GH-releasing hormone [1 microgram/kg IV bolus; responses expressed as maximum percentage increase above baseline (PERGH)]. Bone mineral density (BMD) of the spine, hip, and total body were measured by dual-energy X-ray absorptiometry. Mean BMD Z-scores of the HPT patients were significantly lower in the femoral neck, Ward's triangle, and trochanter than in controls (all P < 0.05). Mean total body BMD (g/cm2) was also lower in the patient group (1.04 +/- 0.03 versus 1.13 +/- 0.03, P < 0.05). For the subgroup of HPT patients receiving conventional gonadal steroids, mean BMD Z-scores of the lumbar spine also were significantly lower than controls (-1.84 +/- 0.43 versus -0.57 +/- 0.46, P < 0.05). PERGH and IGF-I were correlated with Z-scores of the femoral neck (r = 0.47, P < 0.01; r = 0.45, P < 0.01) and Ward's triangle (r = 0.47, P < 0.01; r = 0.41, P < 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7683247     DOI: 10.1007/bf00298715

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  23 in total

Review 1.  Interpretation of bone densitometry measurements: disadvantages of a percentage scale and a discussion of some alternatives.

Authors:  A M Parfitt
Journal:  J Bone Miner Res       Date:  1990-06       Impact factor: 6.741

2.  Effect of growth hormone on osteoblasts and demonstration of somatomedin-C/IGF I in bone organ culture.

Authors:  H Stracke; A Schulz; D Moeller; S Rossol; H Schatz
Journal:  Acta Endocrinol (Copenh)       Date:  1984-09

3.  Bone mineral status in growth hormone deficiency.

Authors:  R M Shore; R W Chesney; R B Mazess; P G Rose; G J Bargman
Journal:  J Pediatr       Date:  1980-03       Impact factor: 4.406

4.  Effect of cholinergic enhancement by pyridostigmine on growth hormone secretion in obese adults and children.

Authors:  E Ghigo; E Mazza; A Corrias; E Imperiale; S Goffi; E Arvat; J Bellone; C De Sanctis; E E Müller; F Camanni
Journal:  Metabolism       Date:  1989-07       Impact factor: 8.694

5.  Increased activity of insulin-like growth factor (IGF) in osteoblastic cells in the presence of growth hormone (GH): positive correlation with the presence of the GH-induced IGF-binding protein BP-3.

Authors:  M Ernst; G A Rodan
Journal:  Endocrinology       Date:  1990-08       Impact factor: 4.736

6.  Effects of human growth hormone in men over 60 years old.

Authors:  D Rudman; A G Feller; H S Nagraj; G A Gergans; P Y Lalitha; A F Goldberg; R A Schlenker; L Cohn; I W Rudman; D E Mattson
Journal:  N Engl J Med       Date:  1990-07-05       Impact factor: 91.245

7.  Impaired growth hormone secretion in the adult population: relation to age and adiposity.

Authors:  D Rudman; M H Kutner; C M Rogers; M F Lubin; G A Fleming; R P Bain
Journal:  J Clin Invest       Date:  1981-05       Impact factor: 14.808

8.  Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism.

Authors:  S L Greenspan; D S Oppenheim; A Klibanski
Journal:  Ann Intern Med       Date:  1989-04-01       Impact factor: 25.391

9.  The role of growth hormone in the pathogenesis of postmenopausal osteoporosis.

Authors:  H Rico; A Del Rio; T Vila; R Patiño; F Carrera; D Espinós
Journal:  Arch Intern Med       Date:  1979-11

Review 10.  Serum somatomedin binding proteins: physiologic significance and interference in radioligand assay.

Authors:  W H Daughaday; M Kapadia; I Mariz
Journal:  J Lab Clin Med       Date:  1987-03
View more
  11 in total

1.  Serum levels of insulin-like growth factor (IGF); IGF-binding proteins-3, -4, and -5; and their relationships to bone mineral density and the risk of vertebral fractures in postmenopausal women.

Authors:  T Yamaguchi; M Kanatani; M Yamauchi; H Kaji; T Sugishita; D J Baylink; S Mohan; K Chihara; T Sugimoto
Journal:  Calcif Tissue Int       Date:  2006-01-06       Impact factor: 4.333

Review 2.  Skeletal effects of growth hormone and IGF-I in adults.

Authors:  R Marcus
Journal:  Endocrine       Date:  1997-08       Impact factor: 3.633

3.  Untreated adult GH deficiency is not associated with the development of metabolic risk factors: a long-term observational study.

Authors:  V Gasco; L Roncoroni; M Zavattaro; C Bona; A Berton; E Ghigo; M Maccario; S Grottoli
Journal:  J Endocrinol Invest       Date:  2019-08-22       Impact factor: 4.256

Review 4.  DHEA and the skeleton (through the ages).

Authors:  C M Gordon; J Glowacki; M S LeBoff
Journal:  Endocrine       Date:  1999-08       Impact factor: 3.633

5.  Peripheral bone mineral density in correlation to disease-related predisposing conditions in patients with multiple endocrine neoplasia type 1.

Authors:  P H Kann; D Bartsch; P Langer; J Waldmann; P Hadji; A Pfützner; J Klüsener
Journal:  J Endocrinol Invest       Date:  2011-07-27       Impact factor: 4.256

Review 6.  [Growth hormone therapy in adult patients: a review].

Authors:  Peter Herbert Kann
Journal:  Wien Klin Wochenschr       Date:  2011-05-18       Impact factor: 1.704

Review 7.  Optimizing peak bone mass: what are the therapeutic possibilities?

Authors:  S Adami
Journal:  Osteoporos Int       Date:  1994       Impact factor: 4.507

Review 8.  [Growth hormone therapy in adults. Attempt to assess a decade of use].

Authors:  M Faust; C J Strasburger
Journal:  Internist (Berl)       Date:  2008-05       Impact factor: 0.743

Review 9.  Growth hormone, insulin-like growth factors, and the skeleton.

Authors:  Andrea Giustina; Gherardo Mazziotti; Ernesto Canalis
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

Review 10.  Effects of growth hormone on body composition and bone metabolism.

Authors:  A L Carrel; D B Allen
Journal:  Endocrine       Date:  2000-04       Impact factor: 3.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.